Nanobiotix is trading 5.2% down at $34.00 based on the provided live price, with no clear company-specific negative catalyst emerging for September 18, 2026.
- Recent Phase 1 results for JNJ-1900 were encouraging, with no dose-limiting toxicities or treatment-related Grade 3-or-higher adverse events reported.
- Major U.S. indexes are only modestly lower.
- Technical selling or profit-taking remains possible, but unconfirmed.